November 6, 2012
Clearside Biomedical Announces First Successful Human Dosing in a Safety and Tolerability Study in Patients with Retinal Disease
ATLANTA, GA – Clearside Biomedical, Inc., a privately held company specializing in the research and development of ophthalmic pharmaceuticals, today announced the successful dosing of patients in a safety and tolerability clinical study using its proprietary ocular microinjection platform to deliver therapeutics to treat retinal disease.
July 16, 2012
Coferon, Inc. Announces $12 Million Series B Financing
STONY BROOK, NY – (MARKETWIRE via COMTEX) – Coferon Inc., a privately held, New York-based biotechnology company, today announced that it has closed on a $12 million Series B financing round led by a trio of new venture investors: Hatteras Venture Partners of Durham, N.C.; MedImmune Ventures of Gaithersburg, MD (the corporate venture arm of AstraZeneca Ltd); and Ascent Biomedical Ventures of New York, N.Y.
May 7, 2012
Clinverse Receives $3.8 Million to Expand Its Financial Technology for Clinical Trials
RALEIGH, NC – (BUSINESS WIRE) – Clinverse, Inc., the global cloud-based ecommerce platform provider for clinical buy legit tramadol online trials, announced today that it has closed a $3.8 million Series B round of funding led by Hatteras Venture Partners of Durham, NC. Vital Financial of Bethesda, MD, also participated in this funding round.
January 5, 2012
Clearside Biomedical Launched With Pipeline and Technology Focused on Drugs Delivered to the Back of the Eye
ATLANTA and DURHAM – (Business Wire) – Ophthalmic startup Clearside Biomedical, Inc. and Hatteras Venture Partners announce today that they have launched the company with a $4,000,000 Series A venture financing to fund the initial development of Clearside Biomedical’s ocular microinjection platform and initial clinical testing of Clearside Biomedical’s lead product for Macular Edema and Retinal Vein Occlusion.